Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs (India) Limited has filed copies of newspaper clippings that published the extract of its audited financial results for the quarter and year ended 31st March 2025. The results were published on 21st May 2025 in both Marathi and English editions, in compliance with SEBI's Listing Regulations. The company reported strong growth for FY25. Consolidated total income stood at Rs. 20,947.91 lakhs versus Rs. 15,885.14 lakhs in FY24, while net profit after tax jumped to Rs. 2,494.01 lakhs from Rs. 1,357.52 lakhs. Consolidated EPS rose to Rs. 16.6 from Rs. 9.17. On a standalone basis, total income was Rs. 19,530.26 lakhs (vs Rs. 13,778.75 lakhs) and profit after tax was Rs. 3,115.69 lakhs (vs Rs. 1,757.38 lakhs). The board had approved these results on 19th May 2025.
This is a procedural filing sharing the newspaper publication of already-disclosed Q4/FY25 results — no new financial information. For shareholders, the underlying results show healthy topline growth (~32% consolidated revenue growth) and a sharp rise in net profit (~84%), which is supportive for sentiment, though the filing itself has no direct price impact.